RHHBY Roche Holding AG
RHHBY Roche Holding AG
Healthcare · Drug Manufacturers - General
Desk view
Market read
POC $50.89 · VWAP $52.19 · +9.5% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
1 watchlist
RHHBY Price Structure
Loading timeframes…
Peers
Every watchlist RHHBY belongs to, members best 30-day change first — RHHBY highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech
Against street estimates
How RHHBY's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about RHHBY from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 10 days ago · Oct 7
- Roche Holding AG (SWX:ROP) Stock Price & Overview
- Roche Holding AG (VIE:ROGH) Stock Price & Overview
- Roche Holding AG Ordinary Shares new (ROP)
- Roche Holding AG (RHHBY) Q2 2026 Earnings Call Transcript
- Roche Holding AG entered into a definitive merger agreement to acquire PathAI, Inc. for $1.1 billion. | MarketScreener
RHHBY research tape
11 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.